Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Senzime AB is a company specializing in the development and commercialization of digital solutions for patient monitoring, focusing primarily on postoperative environments. Its core offerings include innovative systems designed to enhance the quality of care by providing continuous and accurate monitoring of neuromuscular function. Senzime’s technology addresses the critical need for preventing residual neuromuscular blockade, thereby improving patient outcomes and reducing hospital stays. The company serves sectors within the healthcare industry, particularly hospitals and surgical centers that require precise patient monitoring during and after surgical procedures. With its headquarters in Sweden, Senzime has positioned itself significantly within the medical technology market, driving advancements in patient safety and operational efficiency. By leveraging cutting-edge biotechnology and digital interfaces, Senzime plays a crucial role in the evolution of healthcare practices, aligning with the growing emphasis on patient-centered care and technological integration in medical processes.
kr 0.35
+kr 0.01 (+3.12%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-115.30% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 77.9% YoY with margins expanding 110.0pp.
Negative free cash flow of -kr 127M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 104M
▲ +77.9% YoY
Net Income (TTM)
-kr 125M
▼ -15.7% YoY
Op. Margin
-114.62%
▲ +110.0pp YoY
ROIC
-27.58%
Cash Flow & Balance Sheet
FCF (TTM)
-kr 116M
▼ -0.7% YoY
Op. Cash Flow (TTM)
-kr 114M
▼ -0.4% YoY
Net Debt
-kr 60M
Net Cash Position
Cash & Equiv.
kr 74M
3Y CAGR: +95.0%
Continue Research
Senzime AB (SEZI.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Senzime AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Senzime AB scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -114.6% operating margin and a -27.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SEZI.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.